Non-Invasive Fat Destruction Device UltraShape Power Gets FDA Clearance

Article

The FDA has approved UltraShape Power (Syneron Medical Ltd) for non-invasive reduction of abdominal circumference through fat cell destruction.

The FDA has approved UltraShape Power (Syneron Medical Ltd) for non-invasive reduction of abdominal circumference through fat cell destruction.

UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat without any actual damage to surrounding tissue including blood vessels, nerves, and muscles. Specifically its USculpt transducer provides a 20% increase in acoustic energy and 32% reduction in abdominal fat layer thickness.

The devices advanced treatment mode allows physicians to treat a full abdomen in close to 30 minutes, and proper wi-fi connections makes remote diagnostics and scheduling support possible.

UltraShape Power’s lighter transducer also enables customized treatment of large and small fat areas. Additionally, the device incorporates a sophisticated treatment and patient management software package with flexible communication options.

Also, according to the clinical studies, patients exhibited a pain score of less than one out of ten-point scale., meaning patients experienced fairly comfortable levels.

According to Suzanne Kilmer, MD, FAAD, Founding Director of the Laser & Skin Surgery Center of Northern California, “UltraShape Power represents the latest advancement in non-thermal focused ultrasound for fat destruction. The device’s unique deployment of higher acoustic energy via its new transducer allows for the precise targeting of small and large pockets of fat with minimal increase in tissue temperature, resulting in a comfortable treatment experience. The outcomes observed using UltraShape Power have been positive and our patient experience has been very satisfactory.”

Recent Videos
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
Signs and Symptoms of Connective Tissue Disease
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
© 2024 MJH Life Sciences

All rights reserved.